Pfizer Inc. $PFE Shares Sold by Cannell & Spears LLC

Cannell & Spears LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 8.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 248,062 shares of the biopharmaceutical company’s stock after selling 23,136 shares during the period. Cannell & Spears LLC’s holdings in Pfizer were worth $6,944,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $26,000. YANKCOM Partnership bought a new position in Pfizer in the fourth quarter worth about $28,000. HFM Investment Advisors LLC lifted its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. boosted its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC bought a new position in Pfizer during the 4th quarter worth $31,000. 68.36% of the stock is currently owned by institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence
• Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945
• Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
• Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook.
• Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns.
• Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Guggenheim decreased their price objective on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a report on Monday, July 13th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. CICC Research started coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price on the stock. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Finally, JPMorgan Chase & Co. cut their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.50.

Pfizer Stock Down 1.9%

Pfizer stock opened at $24.52 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The firm’s fifty day simple moving average is $25.11 and its 200-day simple moving average is $26.16. The company has a market capitalization of $139.78 billion, a P/E ratio of 18.72 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the company earned $0.92 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.